Jump Financial’s CytomX Therapeutics CTMX Stock Holding History

Jump Financial’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.3M	Buy	347,400 +336,676	+3,139%	+$1.29M	0.01%	1065
2026 Q1	$50.4K	Buy	+10,724	New	+$54.4K	﹤0.01%	1789
2024 Q2	–	Sell	-38,578	Closed	-$84.1K	–	1880
2024 Q1	$84.1K	Buy	+38,578	New	+$71.2K	﹤0.01%	1808
2022 Q2	–	Sell	-62,800	Closed	-$168K	–	1687
2022 Q1	$168K	Buy	+62,800	New	+$241K	0.01%	1342
2021 Q4	–	Sell	-17,300	Closed	-$88K	–	1440
2021 Q3	$88K	Buy	+17,300	New	+$92.6K	0.01%	987
2021 Q1	–	Sell	-15,900	Closed	-$104K	–	996
2020 Q4	$104K	Buy	+15,900	New	+$114K	0.02%	865

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Jump Financial's CTMX Position: Q2 2026 in Review

Jump Financial increased its CytomX Therapeutics (CTMX) stake by 3,139% in Q2 2026, buying an estimated $1.29M and bringing the position to 347,400 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #1065.

Jump Financial first reported a position in CTMX in Q4 2020 and has held it in 6 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Jump Financial held 347,400 shares of CytomX Therapeutics worth $1.3M as of Q2 2026.
Jump Financial bought 336,676 CytomX Therapeutics shares in Q2 2026, an estimated $1.29M.
CytomX Therapeutics made up 0.01% of Jump Financial's portfolio in Q2 2026, its #1065 holding.
Jump Financial first reported a position in CytomX Therapeutics in Q4 2020 and has held it in 6 quarters since.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.